Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma
Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
Retinoblastoma (RB) is the most common intraocular tumor of childhood. Recurrent or
refractory disease following therapy most often occurs due to persistence of vitreous disease
and/or retinal reactivation of the main tumor mass. With this treatment protocol,
investigators seek to identify a less invasive method of local drug delivery that does not
disrupt the eye's integrity.
PRIMARY OBJECTIVE:
- To determine the safety and toxicity profile associated with intravitreal carboplatin
for the treatment of recurrent or progressive intraocular retinoblastoma with vitreous
seeding.
SECONDARY OBJECTIVES:
- To estimate the ocular salvage rate after treatment with intravitreal carboplatin in
patients with recurrent or progressive intraocular retinoblastoma with vitreous seeding.
- To evaluate the effects of intravitreal carboplatin therapy on the histopathology of
eyes enucleated for progressive or recalcitrant disease while on therapy.
Phase:
Phase 1
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Treatments:
Carboplatin Dexamethasone, neomycin, polymyxin B drug combination